Literature DB >> 7579369

Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients.

L Ochs1, X O Shu, J Miller, H Enright, J Wagner, A Filipovich, W Miller, D Weisdorf.   

Abstract

Infectious complications are a major cause of morbidity and mortality after allogeneic bone marrow transplantation (BMT). We have evaluated the incidence of late infections (beyond day +50) in recipients of related (RD) and unrelated donor (URD) allogeneic BMT, factors associated with increased risks of infection, and the impact of the late infections on survival. Between 1989 and 1991, 249 patients received an RD (n = 151) or URD (n = 98) allogeneic BMT at the University of Minnesota and all late infections were investigated. Three hundred sixty-seven late infectious events developed in 162 patients between 50 days and 2 years after BMT. The incidence of any late infection was greater in URD versus RD recipients (84.7% v 68.2%, respectively; P = .009). In multivariate analysis, advanced graft-versus-host disease (GVHD) was significantly associated with late infections. The effect of GVHD was apparent only in RD recipients (relative risk [RR], 2.29; P = .003), whereas URD recipients, with or without GVHD, had more late infections compared with RD recipients without GVHD. Multivariate analysis showed that late posttransplantation infections were the dominant independent factor associated with increased nonrelapse mortality (RR, 5.5; P = .0001), resulting in improved 3-year survival for RD versus URD recipients (49.9% +/- 8% v 34.4% +/- 10%; P = .004). In this study, we observed that late infections are more frequent in URD recipients, resulting in substantially higher nonrelapse mortality. This prolonged period of increased infectious risk in URD recipients suggests the need for aggressive surveillance and therapy of late infections and perhaps prolonged antibiotic prophylaxis for all URD BMT recipients.

Entities:  

Mesh:

Year:  1995        PMID: 7579369

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

1.  Antigen-specific T-lymphocyte function after cord blood transplantation.

Authors:  Geoff Cohen; Shelly L Carter; Kenneth I Weinberg; Bernadette Masinsin; Eva Guinan; Joanne Kurtzberg; John E Wagner; Nancy A Kernan; Robertson Parkman
Journal:  Biol Blood Marrow Transplant       Date:  2006-12       Impact factor: 5.742

2.  Enhanced T-cell reconstitution by hematopoietic progenitors expanded ex vivo using the Notch ligand Delta1.

Authors:  Mari H Dallas; Barbara Varnum-Finney; Paul J Martin; Irwin D Bernstein
Journal:  Blood       Date:  2007-01-09       Impact factor: 22.113

Review 3.  Post-transplant adoptive T-cell immunotherapy.

Authors:  Nicole A Aqui; Carl H June
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

4.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

Review 5.  Thymic T-cell development in allogeneic stem cell transplantation.

Authors:  Werner Krenger; Bruce R Blazar; Georg A Holländer
Journal:  Blood       Date:  2011-03-22       Impact factor: 22.113

6.  Risk factor for death in hematopoietic stem cell transplantation: are biomarkers useful to foresee the prognosis in this population of patients?

Authors:  K S R Massaro; R Macedo; B S de Castro; F Dulley; M S Oliveira; M A S Yasuda; A S Levin; S F Costa
Journal:  Infection       Date:  2014-09-30       Impact factor: 3.553

7.  Rabbit antithymocyte globulin (thymoglobulin) impairs the thymic output of both conventional and regulatory CD4+ T cells after allogeneic hematopoietic stem cell transplantation in adult patients.

Authors:  Il-Kang Na; Friedrich Wittenbecher; Mikalai Dziubianau; Anne Herholz; Angela Mensen; Désirée Kunkel; Olga Blau; Igor Blau; Eckhard Thiel; Lutz Uharek; Carmen Scheibenbogen; Kathrin Rieger; Andreas Thiel
Journal:  Haematologica       Date:  2012-07-16       Impact factor: 9.941

Review 8.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

9.  The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease.

Authors:  Il-Kang Na; Sydney X Lu; Nury L Yim; Gabrielle L Goldberg; Jennifer Tsai; Uttam Rao; Odette M Smith; Christopher G King; David Suh; Daniel Hirschhorn-Cymerman; Lia Palomba; Olaf Penack; Amanda M Holland; Robert R Jenq; Arnab Ghosh; Hien Tran; Taha Merghoub; Chen Liu; Gregory D Sempowski; Melissa Ventevogel; Nicole Beauchemin; Marcel R M van den Brink
Journal:  J Clin Invest       Date:  2009-12-01       Impact factor: 14.808

10.  Short-term inhibition of p53 combined with keratinocyte growth factor improves thymic epithelial cell recovery and enhances T-cell reconstitution after murine bone marrow transplantation.

Authors:  Ryan M Kelly; Emily M Goren; Patricia A Taylor; Scott N Mueller; Heather E Stefanski; Mark J Osborn; Hamish S Scott; Elena A Komarova; Andrei V Gudkov; Georg A Holländer; Bruce R Blazar
Journal:  Blood       Date:  2009-12-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.